{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:08:29Z","timestamp":1791382109926,"version":"4.3.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fonds de recherche du Qu\u00e9bec\u2013Sant\u00e9\u2019s Clinical Research Scholars awards."},{"name":"Oncopole EMC2, a peer-reviewed funding grant that matched unrestricted funds from the Fonds de Recherche du Qu\u00e9bec\u2013Sant\u00e9 public agency, the Cancer Research Society, and Merck Canada."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The tumour sink effect is a phenomenon whereby the sequestration of a radiopharmaceutical in cancer lesions leads to decreased activity concentration in the blood stream and organs. The aim of this sub-analysis of the prospective 3TMPO study (NCT04000776) was to investigate the tumour sink effect on prostate-specific membrane antigen (PSMA) PET imaging in a population of patients with metastatic castration-resistant prostate cancer (mCRPC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Ninety-seven participants underwent <jats:sup>68<\/jats:sup>Ga-PSMA-617 PET\/CT imaging. The activity concentration in the kidney, parotid, spleen, liver and blood was expressed as a percentage of injected activity per cubic centimetre (%IA\/cm<jats:sup>3<\/jats:sup>). The total tumour volume was delineated, and the total lesion fraction (TLF), i.e., the percentage of injected activity sequestered in the tumour, was computed. Participants were stratified into three tumour burden groups: small (TLF\u2009&lt;\u200910%), moderate (10% \u2264 TLF\u2009&lt;\u200925%), and large (TLF\u2009\u2265\u200925%). Weight, lean body weight, body surface area, and estimated glomerular filtration rate (eGFR) were investigated as additional factors affecting biodistribution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The TLF ranged from 0.0 to 43.5%. For all healthy tissues, the %IA\/cm<jats:sup>3<\/jats:sup> was negatively correlated with TLF (<jats:italic>r<\/jats:italic> ranging \u2212\u20090.33 to \u2212\u20090.46; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Patients with a large TLF had significantly lower uptake in all organs when compared to those with a small TLF (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Body habitus indices and\/or eGFR were negatively correlated with the %IA\/cm<jats:sup>3<\/jats:sup> of the parotid, liver and blood (<jats:italic>r<\/jats:italic> ranging \u2212\u20090.23 to \u2212\u20090.33; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Combining predictive variables, the term [BSA \/ (1\u2013TLF)] tended to yield the strongest negative correlations with healthy tissues %IA\/cm<jats:sup>3<\/jats:sup> (<jats:italic>r<\/jats:italic> ranging \u2212\u20090.33 to \u2212\u20090.63; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The tumour sink effect was observed in a cohort of mCRPC patients scanned with <jats:sup>68<\/jats:sup>Ga-PSMA-617. This finding strongly suggests that patients with a large TLF are likely to receive lower absorbed doses to organs at risk \u2013 i.e., be undertreated from a dosimetry perspective \u2013 following a fixed-activity regime of <jats:sup>177<\/jats:sup>Lu-PSMA-617 radiopharmaceutical therapy, as commonly practiced. Individual factors such as body habitus and renal function further impact the biodistribution of PSMA radiopharmaceuticals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>NCT04000776, registered on 2019-06-27.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40644-025-00910-z","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T06:51:23Z","timestamp":1752562283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The tumour sink effect on 68Ga-PSMA-PET\/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study"],"prefix":"10.1186","volume":"25","author":[{"given":"Atefeh","family":"Zamanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Alexandre","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Arsenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"April","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Juneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Plouznikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric E.","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick O.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Pouliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Mathieu","family":"Beauregard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"910_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","volume":"24","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, et al. Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:597\u2013610.","journal-title":"Lancet Oncol"},{"key":"910_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"910_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"910_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","volume":"39","author":"JM Beauregard","year":"2012","unstructured":"Beauregard JM, Hofman MS, Kong G, Hicks RJ. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:50\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"910_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60:517\u201323.","journal-title":"J Nucl Med"},{"issue":"supplement 2","key":"910_CR6","first-page":"2552","volume":"63","author":"JM Beauregard","year":"2022","unstructured":"Beauregard JM, Bergeron M, Bouvet G, April G, Arseneult F, Beaulieu A, et al. Whole-body D50: a pragmatic quantitative SPECT-based dosimetric index for personalized PSMA radiopharmaceutical therapy with 177Lu-PSMA-I&T. J Nucl Med. 2022;63(supplement 2):2552.","journal-title":"J Nucl Med"},{"key":"910_CR7","first-page":"1710","volume":"65","author":"F Pouliot","year":"2024","unstructured":"Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, et al. Intrapatient intermetastatic heterogeneity determined by triple-tracer PET imaging in mCRPC patients and correlation to survival: the 3TMPO cohort study. J Nucl Med 2024 J Nucl Med. 2024;65:1710\u20137.","journal-title":"J Nucl Med 2024 J Nucl Med"},{"key":"910_CR8","doi-asserted-by":"publisher","first-page":"55094","DOI":"10.18632\/oncotarget.19049","volume":"8","author":"FC Gaertner","year":"2017","unstructured":"Gaertner FC, Halabi K, Ahmadzadehfar H, K\u00fcrpig S, Eppard E, Kotsikopoulos C, et al. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget. 2017;8:55094\u2013103.","journal-title":"Oncotarget"},{"key":"910_CR9","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.3390\/cancers15153878","volume":"15","author":"D Groener","year":"2023","unstructured":"Groener D, Wichert J, Adams M, Mader N, Klimek K, Nguyen Ngoc C, et al. Impact of [177Lu]Lu-PSMA-617 radioligand therapy on reference organ uptake assessed by [68Ga]Ga-PSMA-11-PET\/CT. Cancers (Basel). 2023;15:3878.","journal-title":"Cancers (Basel)"},{"key":"910_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s12149-021-01593-9","volume":"35","author":"M Tuncel","year":"2021","unstructured":"Tuncel M, Telli T, Tuncal\u0131 M\u00c7, Karabulut E. Predictive factors of tumor sink effect: insights from 177Lu-prostate-specific membrane antigen therapy. Ann Nucl Med. 2021;35:529\u201339.","journal-title":"Ann Nucl Med"},{"key":"910_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2967\/jnumed.121.261906","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, et al. Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality?? J Nucl Med. 2022;63:226\u201332.","journal-title":"J Nucl Med"},{"key":"910_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11307-019-01375-w","volume":"22","author":"RA Werner","year":"2020","unstructured":"Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, et al. Semiquantitative parameters in PSMA-targeted PET imaging with [18F]DCFPyL: impact of tumor burden on normal organ uptake. Mol Imaging Biol. 2020;22:190\u20137.","journal-title":"Mol Imaging Biol"},{"key":"910_CR13","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.3390\/cancers15092592","volume":"15","author":"C Burgard","year":"2023","unstructured":"Burgard C, Rosar F, Marlowe RJ, Bartholom\u00e4 M, Dewes S, Schaefer-Schuler A, et al. Tumor sink effect with prostate-specific membrane antigen-targeted theranostics in patients with metastatic castration-resistant prostate cancer: intra-individual evaluations. Cancers (Basel). 2023;15:2592.","journal-title":"Cancers (Basel)"},{"issue":"supplement 2","key":"910_CR14","first-page":"2630","volume":"63","author":"JM Beauregard","year":"2022","unstructured":"Beauregard JM, Bergeron M, Bouvet G, Beaulieu A, Arseneult F, April G, et al. Body size and renal function are predictors of healthy tissue dosimetry in PSMA radiopharmaceutical therapy with 177Lu-PSMA-I&T. J Nucl Med. 2022;63(supplement 2):2630.","journal-title":"J Nucl Med"},{"key":"910_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00259-021-05613-8","volume":"49","author":"JM Beauregard","year":"2022","unstructured":"Beauregard JM, Rahmim A. Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF). Eur J Nucl Med Mol Imaging. 2022;49:424\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"910_CR16","first-page":"94","volume-title":"Research on obesity: a report of the DHSS\/MRC group","author":"WPT James","year":"1976","unstructured":"James WPT, Waterlow JC, DHSS\/MRC Group on Obesity Research. Research on obesity: a report of the DHSS\/MRC group. London: H.M.S.O; 1976. p. 94."},{"key":"910_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"R Mosteller","year":"1987","unstructured":"Mosteller R. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098\u20131098.","journal-title":"N Engl J Med"},{"key":"910_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro A III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"910_CR19","doi-asserted-by":"crossref","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y (Lucy), Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247\u201354.","DOI":"10.7326\/0003-4819-145-4-200608150-00004"},{"issue":"1","key":"910_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"key":"910_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40644-022-00505-y","volume":"22","author":"JM Beauregard","year":"2022","unstructured":"Beauregard JM. Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer. Cancer Imaging. 2022;22:67.","journal-title":"Cancer Imaging"},{"key":"910_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","volume":"46","author":"M Del Prete","year":"2019","unstructured":"Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46:728\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"910_CR23","doi-asserted-by":"crossref","unstructured":"Peters SMB, Hofferber R, Priv\u00e9 BM, de Bakker M, Gotthardt M, Janssen M, et al. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49(4):1101\u201312.","DOI":"10.1007\/s00259-021-05538-2"},{"key":"910_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schom\u00e4cker K, et al. Comparison of [18 F] DCFPyL and [68 ga] Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biology. 2015;17:575\u201384.","journal-title":"Mol Imaging Biology"},{"key":"910_CR25","doi-asserted-by":"crossref","unstructured":"G\u00fchne F, Radke S, Winkens T, K\u00fchnel C, Greiser J, Seifert P, et al. Differences in distribution and detection rate of the [68Ga] Ga-PSMA ligands PSMA-617,-I&T and-11\u2014inter-individual comparison in patients with biochemical relapse of prostate cancer. Pharmaceuticals. 2022;15(1):9.","DOI":"10.3390\/ph15010009"},{"key":"910_CR26","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s00259-017-3688-2","volume":"44","author":"M Del Prete","year":"2017","unstructured":"Del Prete M, Buteau FA, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44:1490\u2013500.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"910_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40658-018-0224-9","volume":"5","author":"M Del Prete","year":"2018","unstructured":"Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, et al. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. EJNMMI Phys. 2018;5:25.","journal-title":"EJNMMI Phys"},{"key":"910_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"910_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40658-021-00363-w","volume":"8","author":"J Zhao","year":"2021","unstructured":"Zhao J, Xue Q, Chen X, You Z, Wang Z, Yuan J, et al. Evaluation of SUVlean consistency in FDG and PSMA PET\/MR with Dixon-, James-, and Janma-based lean body mass correction. EJNMMI Phys. 2021;8:17.","journal-title":"EJNMMI Phys"},{"key":"910_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1148\/radiology.189.3.8234714","volume":"189","author":"KR Zasadny","year":"1993","unstructured":"Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847\u201350.","journal-title":"Radiology"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00910-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00910-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00910-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:03:12Z","timestamp":1757239392000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00910-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["910"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00910-z","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the declaration of Helsinki and received authorization from the central research ethic board and all participants provided written informed consent prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Senior authors J.M.B. and F.P. have received consultancy honoraria from, and are local principal investigators for, Novartis. J.M.B. is a local principal investigator for Point Biopharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}